Cardinal Health will offer the device as a standalone product to hospitals and as part of a customizable kit to address blood culture contamination.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.
The Unity test enables screening for several autosomal recessive conditions from fetal DNA gathered from maternal blood.
Mobidiag signed agreements for its Amplidiag and Novodiag products with Alab in Poland and the Ukraine; Biogenetix in Romania; and Theranostica in Israel.
Hardy Diagnostics has partnered with NG Biotech to exclusively distribute the 15-minute test in the US. It has also brought it through the US regulatory process.
The NG-Test Carba 5 detects and differentiates KPC, OXA-48-like, VIM, IMP, and NDM and provides results in 15 minutes.
The PCR-based test analyzes mitochondrial DNA to detect prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and age.
Aalto sells raw materials for in vitro diagnostics including purified human proteins, monoclonal and polyclonal antibodies, and viral antigens.
The FDA-cleared panel includes tests for salmonella, Shiga toxin-producing Escherichia coli, Shigella, Campylobacter, and Cryptosporidium.
The distributor, Bionuclear Puerto Rico, will give T2 access to approximately 64 hospitals in Puerto Rico and the US Virgin Islands.